{"url_path":"/sec/rdhl/10-k/2026/item-18","section_key":"item-18","section_title":"Item 18 FINANCIAL STATEMENTS**","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1553846/0001104659-26-049055-index.html","accession_number":"0001104659-26-049055","cik":"0001553846","ticker":"RDHL","issuer_name":"RedHill Biopharma Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1553846/0001104659-26-049055-index.html","primary_entity_key":"0001553846","primary_entity_name":"RedHill Biopharma Ltd."},"word_count":66,"has_tables":true,"body_markdown":"**ITEM 18.            FINANCIAL STATEMENTS**\n\nThe financial statements required by this item are found at the end of this Annual Report, beginning on page F-1.\n\nPursuant to Rule 3-09 of Regulation-S-X, the audited financial statements of Talicia Holdings, Inc. as of December 31, 2025, and for the period from (incorporation) September 12, 2025 through December 31, 2025, are incorporated in this Annual Report as Exhibit 15.1.\n\n​"}